Why HbA1c alone is not enough to Detect Insulin Resistance is a question most patients never think to ask — because nobody tells them there is a question to ask. They receive a normal result, their doctor says everything looks fine, and they leave reassured. What they are not told is that HbA1c measures average glucose — and says nothing about the insulin required to produce it.
Every year, millions of people receive a normal HbA1c result and walk away reassured. Their doctor tells them their blood sugar is fine. No follow-up is needed. Come back in a year.
What that conversation does not include — because the test does not capture it — is whether insulin resistance has already been silently operating for years. Whether the pancreas has been compensating with progressively higher insulin output. Whether fasting insulin has been climbing steadily while glucose remains perfectly controlled. Whether the metabolic trajectory is already set toward type 2 diabetes, fatty liver, and cardiovascular disease — just not yet visible on the test that was ordered.
HbA1c is a genuinely useful marker. It is one of the most reliable tools available for diagnosing and monitoring established diabetes. The problem is not the test itself. The problem is using a late-stage marker to screen for an early-stage process — and concluding that a normal result means metabolic health is intact.
It does not. And understanding why requires understanding what HbA1c actually measures, what it structurally cannot detect, and what needs to be measured alongside it.
What you will learn: What HbA1c measures and where its detection window begins | Why insulin resistance can be fully established with a normal HbA1c for a decade or more | The compensatory physiology that keeps glucose — and therefore HbA1c — artificially normal | What the complete early detection marker panel looks like | How to interpret your HbA1c result in proper metabolic context
Clinical Perspective: What I See in Practice
This morning I had a consultation with a patient in their mid-50s — a profile I encounter regularly. They arrived with a folder of lab results spanning several years. HbA1c between 6.0 and 6.5%. Fasting glucose around 160 mg/dL. Liver enzymes within the normal range throughout. They had been monitored annually by their GP and told, year after year, that things were progressing but manageable. No alarm was raised. No additional markers were ordered.
When I ran fasting insulin, it came back at 21 µIU/mL.
That number — sitting alongside a still-moderate HbA1c — tells a story that no standard panel had told this patient in five or more years of regular check-ups. The insulin resistance had not appeared overnight. It had been developing quietly, measurably, for years before the glucose markers moved enough to trigger concern. By the time they reached me, the compensatory phase was already exhausted. The window for early intervention had closed.
This pattern repeats without exception in my practice. The patients are typically in their 50s — though I am seeing increasing numbers in their 40s, often with worse dietary habits and faster progression. Almost universally, they report the same experience: their doctor refused to order fasting insulin, hsCRP, or homocysteine. The panel was glucose, HbA1c, and a lipid profile — interpreted with near-exclusive focus on LDL and fasting glucose. Triglycerides and HDL were reported but not interpreted. Fasting insulin never appeared.
What strikes these patients most in our first consultation is not the diagnosis. It is that they are seeing certain markers — fasting insulin, HOMA-IR, the triglyceride-to-HDL ratio — for the first time in their lives. Nobody had ordered them. Nobody had explained what they measure or why they matter. The metabolic dysfunction had been visible in the data for years. It simply was not being looked for.
The situation is compounded by the near-universal failure to identify NAFLD in this population. In my clinical experience, fatty liver is not a late-stage complication — it is an early metabolic marker that appears alongside hyperinsulinemia, often before HbA1c becomes abnormal. Yet it goes undiagnosed in the overwhelming majority of patients I see, even those who have had multiple rounds of standard blood work. The diagnostic system, particularly within the German healthcare structure, is oriented almost entirely around downstream glucose markers. The upstream hormonal and hepatic signals that precede glucose dysregulation by a decade are systematically overlooked.
By the time a patient finds their way to a metabolic specialist, the preventable window has typically passed. That is the real clinical cost of over-relying on HbA1c.
What HbA1c Actually Measures
HbA1c — glycated hemoglobin — reflects the percentage of hemoglobin molecules in red blood cells that have been irreversibly bound to glucose through a non-enzymatic process called glycation. Because red blood cells have a lifespan of approximately 90–120 days, the HbA1c value represents a rolling average of blood glucose exposure over that period.
This is what makes HbA1c genuinely valuable for monitoring established diabetes. It is not susceptible to day-to-day glucose variability. It is not affected by what was eaten the night before the test. It provides a stable, reproducible index of average glycemic exposure over three months — exactly what is needed to track whether a diabetic patient’s glucose management is improving or deteriorating.
The diagnostic thresholds currently used clinically reflect this:
| HbA1c | Interpretation |
|---|---|
| Below 5.7% | Normal |
| 5.7–6.4% | Prediabetes |
| 6.5% and above | Type 2 diabetes |
These thresholds are well-validated for their intended purpose. The clinical problem arises when they are applied to a different question — not “does this person have diabetes?” but “does this person have early insulin resistance?” — for which they were never designed and are structurally inadequate.
The Compensatory Phase: Why Glucose Stays Normal While Insulin Climbs
To understand why HbA1c misses early insulin resistance, you need to understand the compensatory physiology that precedes glucose dysregulation — and how long it can sustain a false appearance of metabolic normality.
Insulin resistance develops gradually in skeletal muscle first — the primary site of insulin-mediated glucose disposal. As muscle cells become less responsive to insulin’s signal, more insulin is required to clear the same amount of glucose from the bloodstream after a meal. The pancreas responds by secreting more insulin — a state called compensatory hyperinsulinemia.
This compensation is remarkably effective. As long as the pancreatic beta cells can sustain the increased output, blood glucose remains tightly controlled. Postprandial glucose spikes are managed — not because glucose metabolism is efficient, but because insulin output is elevated enough to force glucose clearance despite impaired receptor sensitivity. Fasting glucose stays within the normal range. HbA1c stays below 5.7%.
From the perspective of any glucose-based test — fasting glucose, postprandial glucose, or HbA1c — this individual appears metabolically healthy. The test is working exactly as designed. It is measuring what it measures accurately. But what it is measuring — average glucose — is being artificially maintained by a pancreas working two, three, or four times harder than it should.
This compensatory phase does not last weeks. It lasts years — often a decade or more. The Whitehall II Study, which followed over 6,000 civil servants longitudinally, found that insulin resistance was detectable through fasting insulin measurements approximately 13 years before the clinical diagnosis of type 2 diabetes. Throughout most of that window, HbA1c remained entirely within the normal range.
The glucose is normal. The test is normal. The metabolic trajectory is not.
What Is Happening During the Silent Years
While HbA1c remains reassuringly below 5.7%, the following processes are already underway in individuals with established compensatory hyperinsulinemia:
Fasting insulin is elevated and rising. The fasting insulin level — which directly quantifies the pancreatic output required to maintain baseline glucose — is climbing steadily. Values above 10 µIU/mL indicate meaningful insulin resistance. Values above 15 µIU/mL indicate established hyperinsulinemia that warrants immediate intervention. Both can exist with a perfectly normal HbA1c.
Visceral fat is accumulating. Chronically elevated insulin drives preferential fat deposition into visceral adipose depots — the metabolically active intra-abdominal fat that releases pro-inflammatory cytokines and free fatty acids directly into the portal circulation. Waist circumference is rising even as the scale and the HbA1c remain unchanged.
Hepatic fat is accumulating. As described in detail in the post on how insulin resistance drives fatty liver, elevated insulin activates hepatic de novo lipogenesis via SREBP-1c while simultaneously failing to suppress adipose free fatty acid spillover. Liver fat accumulates through both pathways — with normal liver enzymes and normal HbA1c throughout.
Dyslipidemia is developing. Hyperinsulinemia drives hepatic VLDL triglyceride synthesis and suppresses HDL cholesterol — producing the classic atherogenic lipid pattern of elevated triglycerides and low HDL. The triglyceride-to-HDL ratio is rising. Cardiovascular risk is increasing. HbA1c is normal.
Beta cell strain is accumulating. The pancreas cannot sustain compensatory hypersecretion indefinitely. Each year of sustained overwork accelerates the progressive loss of beta cell mass and function that will eventually tip the system from compensation into frank glucose dysregulation. By the time HbA1c reaches 5.7% — the prediabetes threshold — beta cell function is already compromised by an estimated 50% in many individuals.
This is the clinical cost of relying on HbA1c alone: a decade or more of progressive metabolic damage occurring beneath the detection threshold of the test being used to screen for it.
The Structural Limitations of HbA1c
Beyond the compensatory physiology described above, HbA1c has several structural limitations that further reduce its reliability as an early metabolic screening tool.
It reflects average glucose, not glucose variability. Two individuals can have identical HbA1c values with completely different postprandial glucose profiles. One may have smooth, moderate glucose excursions throughout the day. The other may have sharp, high-amplitude spikes after every meal — driven by insulin resistance — that average out to the same number. The glycemic damage from repeated high-amplitude spikes is not captured by an averaged value.
It is affected by red blood cell turnover. Any condition that alters red blood cell lifespan — hemolytic anemia, iron deficiency anemia, recent blood loss, hemoglobin variants — will artificially lower or raise HbA1c independent of actual glucose control. In populations with high prevalence of hemoglobin variants — including individuals of African, Mediterranean, or South Asian descent — HbA1c reliability is further reduced.
It has poor sensitivity in the prediabetes range. Multiple studies have confirmed that HbA1c in the 5.7–6.4% prediabetes range has poor sensitivity for detecting impaired glucose tolerance when compared against an oral glucose tolerance test. A significant proportion of individuals with impaired glucose tolerance — a more advanced stage of insulin dysregulation — have an HbA1c below 5.7%. The test misses them entirely.
It says nothing about insulin. This is the most fundamental limitation. HbA1c is a glucose marker. It contains zero information about the hormonal effort required to produce the glucose result it reports. A normal HbA1c achieved with normal insulin is metabolically different from a normal HbA1c achieved with triple the insulin output — but the test cannot distinguish between them.
The Complete Early Detection Panel
If HbA1c must always be paired with additional markers to provide a meaningful picture of early metabolic health, what does that complete panel look like?
The following markers together constitute a clinically comprehensive early metabolic screen — one that captures insulin resistance during the compensatory phase, years before glucose becomes abnormal.
Fasting Insulin The single most informative addition to any metabolic panel. Measured after a 10–12 hour overnight fast, fasting insulin directly quantifies the pancreatic output required to maintain baseline glucose — and is therefore a direct proxy for the degree of systemic insulin resistance. It must be specifically requested; it is not included in standard blood panels.
Interpret against physiologically meaningful thresholds — not laboratory reference ranges:
| Fasting Insulin | Clinical Significance |
|---|---|
| Below 5 µIU/mL | Optimal — true insulin sensitivity |
| 5–10 µIU/mL | Acceptable — monitor closely |
| 10–15 µIU/mL | Early hyperinsulinemia — intervene |
| 15–25 µIU/mL | Established IR — address urgently |
| Above 25 µIU/mL | Severe — high risk T2D, CVD, NAFLD |
A fasting insulin of 14 µIU/mL with an HbA1c of 5.3% is not a reassuring result. It is early hyperinsulinemia with glucose currently being controlled at significant pancreatic cost.
HOMA-IR HOMA-IR combines fasting insulin and fasting glucose into a single index of insulin resistance severity: (Fasting Insulin × Fasting Glucose in mmol/L) ÷ 22.5. A value below 1.0 is optimal. Above 2.0 indicates significant insulin resistance. Above 2.9 is associated with substantially elevated cardiovascular and metabolic risk. HOMA-IR is particularly useful for tracking change over time — it provides a single number that reflects improvement or deterioration in the insulin-glucose relationship across serial measurements.
Fasting Glucose Fasting glucose remains a useful component of the panel — not as a standalone screen but as an input into HOMA-IR and as a marker of how far compensation has progressed. A fasting glucose consistently in the upper normal range — 95–99 mg/dL (5.3–5.5 mmol/L) — in combination with elevated fasting insulin indicates that compensation is beginning to strain. The glucose is still technically normal. The direction of travel is not.
Triglyceride-to-HDL Ratio The triglyceride-to-HDL ratio is one of the most robust and underutilized clinical proxies for insulin resistance. Hyperinsulinemia drives hepatic VLDL triglyceride synthesis and suppresses HDL cholesterol through well-characterized mechanisms. The resulting dyslipidemia — elevated triglycerides, low HDL — is a direct metabolic fingerprint of chronically elevated insulin. A ratio above 2.0 using mg/dL units (or above 0.9 using mmol/L) is clinically significant and strongly associated with insulin resistance independent of other markers. It is also highly actionable — a falling triglyceride-to-HDL ratio over time is one of the most reliable confirmations that a metabolic intervention is working.
Waist Circumference and Waist-to-Height Ratio Visceral adiposity is both a cause and a consequence of insulin resistance — and is entirely invisible to HbA1c. Waist circumference above 94 cm in men or 80 cm in women indicates metabolically significant central fat accumulation regardless of BMI or glucose values. Waist-to-height ratio above 0.5 is a simple and validated threshold applicable across ethnicities and body types. These are not vanity metrics. They are direct physical markers of the visceral fat depot that drives portal free fatty acid spillover and inflammatory cytokine release — the same mechanisms that sustain and amplify insulin resistance.
Postprandial Glucose Response Where continuous glucose monitoring is accessible, it provides direct insight into the amplitude and duration of postprandial glucose excursions — information that is averaged away by HbA1c. Repeated excursions above 140 mg/dL (7.8 mmol/L) after meals, in an individual with a normal HbA1c, indicate significant postprandial insulin dysregulation and impaired glucose disposal capacity. This is the earliest functional sign that the compensatory insulin response is becoming insufficient to manage postprandial glucose loads efficiently.
How to Read Your HbA1c Result in Proper Context
A normal HbA1c is not meaningless. It confirms that average glucose over the preceding three months has been within an acceptable range — which is genuinely useful information. The error is treating it as sufficient.
Here is a practical framework for contextualizing any HbA1c result:
HbA1c below 5.7% with fasting insulin below 5 µIU/mL and HOMA-IR below 1.0: This is genuine metabolic health. The glucose result is not being achieved at the cost of excessive insulin output. No intervention indicated beyond maintaining current habits.
HbA1c below 5.7% with fasting insulin above 10 µIU/mL: This is the critical undetected window. Insulin resistance is present and the pancreas is compensating. The HbA1c is normal precisely because compensation is still working — not because metabolism is healthy. Lifestyle intervention is indicated immediately. This is the profile that standard screening misses entirely and that represents the highest-value intervention opportunity.
HbA1c 5.7–6.4% with fasting insulin above 15 µIU/mL: Compensation is beginning to strain. Beta cell function is already under significant load. Glucose dysregulation is emerging. Both markers are now abnormal and the full metabolic picture — including HOMA-IR, lipids, and body composition — warrants urgent assessment.
HbA1c above 6.5%: Type 2 diabetes by current diagnostic criteria. Beta cell compensation has failed or is failing. HbA1c is now appropriate as a monitoring tool for glucose management. The upstream insulin resistance that drove this outcome has been present — and detectable through fasting insulin — for years prior to this point.
A Note on Uncertainty
HbA1c is not a flawed test — it is a misapplied one. In its intended clinical context — monitoring glycemic control in established diabetes — it performs reliably and provides genuinely important information. The criticism in this article is directed at its use as a primary early screening tool for insulin resistance, for which it was not designed and at which it structurally underperforms.
The optimal thresholds for fasting insulin cited here are derived from epidemiological and mechanistic research rather than from a single definitive randomized controlled trial. Different clinicians draw slightly different lines. What the evidence consistently supports is that lower fasting insulin — within a physiological range — is associated with better long-term metabolic, cardiovascular, and cognitive outcomes. The direction of the evidence is clear even where precise thresholds remain in active discussion.
Next Steps
If you have received a normal HbA1c result and have not had fasting insulin measured alongside it, request it at your next blood draw. It is inexpensive, widely available, and provides the one piece of information that HbA1c structurally cannot: how hard your pancreas is working to produce that normal glucose result.
A normal HbA1c with a fasting insulin above 10 µIU/mL is not reassurance. It is an early warning that the standard screening process was not designed to deliver — and that you now have the opportunity to act on before the window closes.
The question is not whether your average glucose is normal. The question is what it is costing your metabolism to keep it that way.
People Also Ask
Can HbA1c be normal with insulin resistance?
Yes — and this is the defining clinical gap in standard metabolic screening. Insulin resistance can be fully established for a decade or more while HbA1c remains below 5.7%. The compensatory insulin hypersecretion that maintains normal glucose is invisible to HbA1c. Fasting insulin is the test that detects it.
What is a normal HbA1c but high insulin?
A normal HbA1c with elevated fasting insulin — above 10 µIU/mL — indicates that blood glucose is being maintained at the cost of compensatory hyperinsulinemia. This is the earliest detectable stage of metabolic dysfunction and represents the highest-value intervention window. Standard screening will not flag this combination.
Why does HbA1c miss early insulin resistance?
HbA1c measures average glucose — not insulin. In early insulin resistance, the pancreas compensates by secreting more insulin to maintain normal glucose levels. HbA1c reports the glucose result without any information about the hormonal effort required to produce it. It cannot distinguish between normal glucose achieved efficiently and normal glucose achieved through compensatory hyperinsulinemia.
What should I test alongside HbA1c?
The complete early metabolic panel includes fasting insulin, HOMA-IR, fasting glucose, triglyceride-to-HDL ratio, and waist circumference. Together these markers capture insulin resistance during the compensatory phase — years before HbA1c becomes abnormal. Fasting insulin is the single most important addition to any standard metabolic screen.
At what HbA1c level should I be concerned?
The clinical prediabetes threshold is 5.7%. But this question misses the more important point: HbA1c can be below 5.7% while fasting insulin is significantly elevated and insulin resistance is well established. Concern is more appropriately triggered by the combination of markers — particularly fasting insulin above 10 µIU/mL — than by HbA1c alone.
Is HbA1c useful at all for detecting insulin resistance?
HbA1c is useful as one component of a broader panel — particularly for confirming that glucose dysregulation has not yet emerged and for monitoring trend over time. It becomes clinically meaningful for insulin resistance detection only when interpreted alongside fasting insulin and HOMA-IR. In isolation it is insufficient for early metabolic screening.
About the Author
Morteza Ariana is a State-Certified Functional Nutritionist based in Germany, specializing in insulin resistance, type 2 diabetes, and root-cause metabolic restoration. He holds advanced training in systems-based physiology and has worked with patients across the U.S. and Europe for over 10 years.
His clinical framework is built around a core principle that mainstream medicine consistently overlooks: chronically elevated insulin — not blood glucose — is the earliest and most actionable driver of metabolic disease. That conviction was shaped in part by his own experience with hyperinsulinemia in 2016, and deepened through a decade of clinical practice and the study of leading researchers in metabolic medicine including Benjamin Bikman, Joseph Kraft, Gerald Reaven, Jason Fung, and Stephen Phinney.
His work focuses on identifying and correcting the upstream metabolic signals — insulin load, liver-gut axis dysfunction, circadian misalignment, and micronutrient gaps — that standard screening misses entirely. Patient outcomes are documented, anonymized, and published on this site.
If this resonates, the next step is clarity
The Metabolic Restoration Blueprint is a structured 12-week framework designed to correct upstream metabolic drivers — not just manage symptoms.
Key References
- Tabák AG, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215–2221.
- Kraft JR. Detection of diabetes mellitus in situ (occult diabetes). Laboratory Medicine. 1975;6(2):10–22.
- Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.
- Yudkin JS, et al. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia. 1990;33(4):208–215.
- Buell C, et al. Diagnosis of type 2 diabetes and prediabetes among adolescents and young adults: comparison of fasting glucose, HbA1c, and OGTT. Journal of Pediatric Endocrinology and Metabolism. 2010;23(8):863–868.
- Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. Journal of Biomedicine and Biotechnology. 2010;2010:476279.
- Facchini FS, et al. Insulin resistance as a predictor of age-related diseases. Journal of Clinical Endocrinology and Metabolism. 2001;86(8):3574–3578.
- Despres JP, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. New England Journal of Medicine. 1996;334(15):952–957.